Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: AHM who wrote (874)	7/10/1998 11:29:00 AM
From: AHM	Read Replies (2) \| Respond to of 1510

The following paragraph was in today's thestreet.com in an article that analyzed AGPH in depth - its comments are not favorable towards Remune: QUOTE Johnson's (Peter Johnson, AGPH CEO) rush to license even led him to do a deal for Immune Response's (IMNR:Nasdaq) Remune, which was once was supposed to be a vaccine for AIDS and now is meant to act as an immune system enhancer. But analysts consider this a controversial move, since after years of testing it continues to be unclear what place, if any, Remune will have in AIDS treatment. Immune Response stock rose about 55% in the days before the conference but fell more than 20% during and after the meeting. END QUOTE Since trading volumes were large when today's 10:36 7/8ths dip occurred, it seems as if a major investor decided to get out. Several trades at this time were for 7,500 and 10,000 shares each - with many in the 1,000's and up. I wonder if this article caused this bailout and how much more selling will be seen today.